Though bankers remain broadly upbeat about 2024, even they admit that after months of headfakes failed to sustain activity, a true return to health could take months.
The unicorns and decacorns lining up for the long-awaited return of mega-listings in 2024 are worthy candidates. They were worthy this year, too – and yet, here we are.
From Reddit Inc. to Syngenta Group to CVC Capital Partners, debuts meant to restore sickly global initial public offering activity to health have been pushed back, sometimes repeatedly. Companies and investors have yet to entirely bridge the gap between their respective valuation expectations, set during boom times fueled by cheap money.
